{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:43:02Z","timestamp":1793130182833,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000261","name":"MS Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Michael Smith Foundation for Health Research Trainee Award"},{"DOI":"10.13039\/100002732","name":"Christopher Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002732","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.msard.2020.102566","type":"journal-article","created":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T12:35:35Z","timestamp":1601901335000},"page":"102566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Safety of dimethyl fumarate for multiple sclerosis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3760-832X","authenticated-orcid":false,"given":"Geoffrey","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8381-5253","authenticated-orcid":false,"given":"Huah Shin","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5804-2535","authenticated-orcid":false,"given":"Helen","family":"Tremlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.msard.2020.102566_bib0001","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1007\/s00415-015-7842-0","article-title":"High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991-2010)","volume":"262","author":"Kingwell","year":"2015","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2020.102566_bib0002","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States: a population-based estimate using health claims data","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2020.102566_bib0003","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/jnnp-2011-300616","article-title":"Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada","volume":"83","author":"Kingwell","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2020.102566_bib0004","unstructured":"National Multiple Sclerosis Society. Medications, Accessed 8-Oct-2020. 2020 https:\/\/www.nationalmssociety.org\/Treating-MS\/Medications."},{"key":"10.1016\/j.msard.2020.102566_bib0005","unstructured":"Biogen. Tecfidera (dimethyl fumarate delayed-release capsules) product monograph. https:\/\/www.biogen.ca\/content\/dam\/corporate\/en_CA\/pdfs\/products\/TECFIDERA\/Tecfidera_PM_EN_Dec2017_v2.pdf. Updated 2017. Accessed May 15, 2019."},{"issue":"4","key":"10.1016\/j.msard.2020.102566_bib0007","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(10)70065-7","article-title":"Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care","volume":"10","author":"Tacconelli","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.msard.2020.102566_bib0008","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated march 2011]","year":"2011"},{"key":"10.1016\/j.msard.2020.102566_bib0009","doi-asserted-by":"crossref","first-page":"i157","DOI":"10.1136\/bmj.i157","article-title":"PRISMA harms checklist: improving harms reporting in systematic reviews","volume":"352","author":"Zorzela","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2020.102566_bib0010","series-title":"Safety Monitoring of Medicinal Products. Guidelines For Setting Up and Running a Pharmacovigilance Centre","year":"2000"},{"key":"10.1016\/j.msard.2020.102566_bib0011","unstructured":"US Food and Drug Administration. Reporting serious problems to FDA - what is a serious adverse event? https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event. Updated 2016. Accessed Jun 25, 2019."},{"key":"10.1016\/j.msard.2020.102566_bib0012","unstructured":"The Cochrane Collaboration. Review manager (RevMan) [computer program] version 5.3. 2014."},{"key":"10.1016\/j.msard.2020.102566_bib0013","unstructured":"Wells G.A., Shea B., O'Connell D., Peterson J., Welch V., Losos M., Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Updated 2019."},{"issue":"2","key":"10.1016\/j.msard.2020.102566_bib0014","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40120-017-0080-x","article-title":"Effectiveness and safety of dimethyl fumarate treatment in relapsing multiple sclerosis patients: real-world evidence","volume":"6","author":"Alroughani","year":"2017","journal-title":"Neurol. Ther."},{"issue":"4","key":"10.1016\/j.msard.2020.102566_bib0015","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.msard.2015.06.002","article-title":"Effects of dimethyl fumarate on lymphocyte subsets","volume":"4","author":"Berkovich","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2020.102566_bib0016","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/acn3.676","article-title":"Dimethyl fumarate treatment induces lipid metabolism alterations that are linked to immunological changes","volume":"6","author":"Bhargava","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2020.102566_bib0017","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.msard.2018.02.028","article-title":"Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: a multicenter retrospective observational study (STRATEGY)","volume":"22","author":"Cohan","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2020.102566_bib0018","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/ene.13839","article-title":"Dimethyl fumarate and teriflunomide for multiple sclerosis in a real-life setting: a French retrospective cohort study","volume":"26","author":"Conde","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2020.102566_bib0019","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418796404","article-title":"Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in relapsing-remitting multiple sclerosis: an Italian real-word multicenter experience","volume":"11","author":"D\u2019Amico","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"12","key":"10.1016\/j.msard.2020.102566_bib0020","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1080\/03007995.2017.1380616","article-title":"Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon beta-1a or dimethyl fumarate: a real-world study","volume":"33","author":"Ernst","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"issue":"5","key":"10.1016\/j.msard.2020.102566_bib0021","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1177\/1352458517703799","article-title":"Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS","volume":"24","author":"Fleischer","year":"2018","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2020.102566_bib0022","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7224\/1537-2073.2014-101","article-title":"Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis (MANAGE)","volume":"18","author":"Fox","year":"2016","journal-title":"Int. J. MS Care"},{"issue":"12","key":"10.1016\/j.msard.2020.102566_bib0023","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102566_bib0024","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418768775","article-title":"Incidence and mitigation of gastrointestinal events in patients with relapsing-remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE)","volume":"11","author":"Gold","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"2","key":"10.1016\/j.msard.2020.102566_bib0025","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1352458516649037","article-title":"Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study","volume":"23","author":"Gold","year":"2017","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.msard.2020.102566_bib0026","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2020.102566_bib0027","article-title":"Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up","volume":"3","author":"Hersh","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"9648","key":"10.1016\/j.msard.2020.102566_bib0028","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(08)61619-0","article-title":"Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study","volume":"372","author":"Kappos","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.msard.2020.102566_bib0029","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1007\/s00415-018-8831-x","article-title":"A multicentRE observational analysiS of PErsistenCe to treatment in the new multiple sclerosis era: the RESPECT study","volume":"265","author":"Lanzillo","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102566_bib0030","first-page":"1","article-title":"Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance","author":"Longbrake","year":"2015","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"8","key":"10.1016\/j.msard.2020.102566_bib0031","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1007\/s00415-018-8916-6","article-title":"Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study","volume":"265","author":"Mallucci","year":"2018","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2020.102566_bib0032","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00415-016-8175-3","article-title":"Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study","volume":"263","author":"Miclea","year":"2016","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2020.102566_bib0033","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40120-019-0127-2","article-title":"Real-world characterization of dimethyl fumarate-related gastrointestinal events in multiple sclerosis: management strategies to improve persistence on treatment and patient outcomes","volume":"8","author":"Min","year":"2019","journal-title":"Neurol. Ther."},{"issue":"10","key":"10.1016\/j.msard.2020.102566_bib0034","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40263-018-0543-3","article-title":"Safety and efficacy of dimethyl fumarate in multiple sclerosis: an Italian, multicenter, real-world study","volume":"32","author":"Mirabella","year":"2018","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.msard.2020.102566_bib0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12883-018-1220-3","article-title":"A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries","volume":"19","author":"Saida","year":"2019","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2020.102566_bib0036","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.msard.2018.05.007","article-title":"Real-life persistence and tolerability with dimethyl fumarate","volume":"24","author":"Sejbaek","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2020.102566_bib0037","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1177\/1352458517709956","article-title":"Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center","volume":"24","author":"Smoot","year":"2018","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.msard.2020.102566_bib0006","article-title":"Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis","volume":"2015","author":"Tramacere","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.msard.2020.102566_bib0038","article-title":"Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: two-year experience","volume":"3","author":"Vollmer","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"1","key":"10.1016\/j.msard.2020.102566_bib0039","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s13104-016-2243-8","article-title":"The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis","volume":"9","author":"Wicks","year":"2016","journal-title":"BMC Res. Notes"},{"issue":"6","key":"10.1016\/j.msard.2020.102566_bib0040","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/1756285616661929","article-title":"Efficacy and tolerability of dimethyl fumarate in White-, African- and Hispanic- Americans with multiple sclerosis","volume":"9","author":"Zhovtis Ryerson","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"5","key":"10.1016\/j.msard.2020.102566_bib0041","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2217\/cer-2018-0135","article-title":"Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world teri-RADAR study","volume":"8","author":"Zivadinov","year":"2019","journal-title":"J. Comp. Eff. Res."},{"issue":"7168","key":"10.1016\/j.msard.2020.102566_bib0042","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/bmj.317.7168.1309","article-title":"Confidence intervals for the number needed to treat","volume":"317","author":"Altman","year":"1998","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.msard.2020.102566_bib0043","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","article-title":"Better reporting of harms in randomized trials: an extension of the CONSORT statement","volume":"141","author":"Ioannidis","year":"2004","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.msard.2020.102566_bib0044","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024537","article-title":"Analysis and reporting of adverse events in randomised controlled trials: a review","volume":"9","author":"Phillips","year":"2019","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.msard.2020.102566_bib0045","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1007\/s12325-019-01085-3","article-title":"Improving the gastrointestinal tolerability of fumaric acid esters: early findings on gastrointestinal events with diroximel fumarate in patients with relapsing-remitting multiple sclerosis from the phase 3, open-label EVOLVE-MS-1 study","volume":"36","author":"Palte","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.msard.2020.102566_bib0046","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fimmu.2018.00138","article-title":"Understanding progressive multifocal leukoencephalopathy risk in multiple sclerosis patients treated with immunomodulatory therapies: a bird\u2019s eye view","volume":"9","author":"Mills","year":"2018","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.msard.2020.102566_bib0047","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1177\/1352458518786075","article-title":"Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients","volume":"25","author":"Oshima","year":"2018","journal-title":"Mult. Scler."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820306404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820306404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:54:22Z","timestamp":1761900862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820306404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":47,"alternative-id":["S2211034820306404"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102566","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of dimethyl fumarate for multiple sclerosis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102566","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102566"}}